- Home
- RZLT vs LUNG Comparison
RZLT vs LUNG Comparison
Compare RZLT & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RZLT
- LUNG
- Stock Information
- Founded
- RZLT 2010
- LUNG 1995
- Country
- RZLT United States
- LUNG United States
- Employees
- RZLT N/A
- LUNG N/A
- Industry
- RZLT Biotechnology: Pharmaceutical Preparations
- LUNG Industrial Specialties
- Sector
- RZLT Health Care
- LUNG Health Care
- Exchange
- RZLT Nasdaq
- LUNG Nasdaq
- Market Cap
- RZLT 226.4M
- LUNG 299.3M
- IPO Year
- RZLT N/A
- LUNG 2020
- Fundamental
- Price
- RZLT $3.05
- LUNG $7.77
- Analyst Decision
- RZLT Strong Buy
- LUNG Strong Buy
- Analyst Count
- RZLT 8
- LUNG 7
- Target Price
- RZLT $12.00
- LUNG $12.64
- AVG Volume (30 Days)
- RZLT 482.0K
- LUNG 464.2K
- Earning Date
- RZLT 05-14-2025
- LUNG 04-30-2025
- Dividend Yield
- RZLT N/A
- LUNG N/A
- EPS Growth
- RZLT N/A
- LUNG N/A
- EPS
- RZLT N/A
- LUNG N/A
- Revenue
- RZLT N/A
- LUNG $83,789,000.00
- Revenue This Year
- RZLT N/A
- LUNG $17.96
- Revenue Next Year
- RZLT N/A
- LUNG $18.35
- P/E Ratio
- RZLT N/A
- LUNG N/A
- Revenue Growth
- RZLT N/A
- LUNG 22.01
- 52 Week Low
- RZLT $1.76
- LUNG $5.46
- 52 Week High
- RZLT $6.19
- LUNG $10.01
- Technical
- Relative Strength Index (RSI)
- RZLT 24.55
- LUNG 52.56
- Support Level
- RZLT $3.25
- LUNG $7.65
- Resistance Level
- RZLT $3.81
- LUNG $8.12
- Average True Range (ATR)
- RZLT 0.22
- LUNG 0.49
- MACD
- RZLT -0.05
- LUNG -0.06
- Stochastic Oscillator
- RZLT 4.35
- LUNG 45.71
About RZLT Rezolute Inc. (NV)
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.